Our injectable naloxone product will use one injection to provide both immediate reversal of opioid overdose, and a sustained NLX dose for protection over the following 8 – 10 hrs to prevent re-narcotization without high- or repeated-dose NLX that would lead to severe adverse events.

Dry eye disease (DED) is among the most frequent causes for eye clinician visits.

DED patients suffer from inadequate lubrication of the eye, which can occur in eyes that produce insufficient tear volume, or tears that evaporate too quickly. Increased inflammation can result, causing further complications and long-term damage. Furthermore, the increasing use of digital devices has been identified as a significant factor contributing to the rise in dry eye cases. Prolonged screen time is associated with reduced blink rates and incomplete blinking, leading to tear film instability and increased evaporation, which are key factors in the development of DED.
‍
Additionally, the blue light emitted by screens can penetrate deep into the eyes, potentially leading to the formation of free radicals and subsequent cellular damage. Primary treatments include tear film restoration using over-the-counter artificial tear drops, and immunomodulating therapy using prescription cyclosporine-A (CsA) eye drops.

DED is one of the most common ocular diseases worldwide, with prevalence of up to 50% of the global, adult population and over 16 million Americans officially diagnosed.

The CDC estimates that 45 million people in the US wear contact lenses. Further, dry eye and related symptoms of irritation are reported by 40% of these wearers, and 25% suffer from moderate to severe symptoms.

Our DDCL administers the clinically proven dry eye therapeutic cyclosporine A for acute cases of dry eye, particularly among existing contact lens wearers.

Allergic conjunctivitis (AC) is an inflammatory condition of the ocular conjunctiva resulting from exposure to pollen, animal dander, and environmental stimuli. Topical eye drops containing antihistamines are the primary treatment method, although limited by burst release, low bioavailability, and poor patient adherence. Further, eye drops are not practical for contact lens wearers as contact lenses prevent effective absorption of existing eye drop solutions targeting allergy-related symptoms.

Over 20% of the U.S. – or approximately 66 million patients – are affected, with wearers of contact lenses (CL) particularly vulnerable due to allergen accumulation on the lens, and restricted tear exchange underneath its surface. Of the 45 million Americans that wear CLs, 40% suffer from allergies causing irritation and disruption of lens wear.

Using our DDCL technology, we can produce sustained release of olopatadine (OPD) in order to more effectively treat AC. Further, production of our DDCL-OPD will be compatible with existing lens manufacturing operations, including all standard physical specifications and refractive capabilities of current commercial contact lenses, consituting a major improvement over both eye drops and available drug delivery lens technology.

Glaucoma is one of the leading causes of irreversible blindness in the United States, affecting nearly 3m Americans today while costing the US economy $2.86 billion every year in direct costs and productivity losses.

By 2050, that number is expected to rise to over 6m due to the aging US population.

Using our DDCL technology, we can produce sustained release of olopatadine (OPD) in order to more effectively treat AC. Further, production of our DDCL-OPD will be compatible with existing lens manufacturing operations, including all standard physical specifications and refractive capabilities of current commercial contact lenses, consituting a major improvement over both eye drops and available drug delivery lens technology.